FDA
-
-
-
-
-
-
-
First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)
-
-
-
-
-
-
-
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
-
-
-
-
-
-
-
Telix doses first patient in Phase 3 kidney cancer drug trial
-
-
-
-
-
-
-
Telix and United Imaging Announce Strategic Theranostics Collaboration
-
-
-
-
-
-
-
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
-
-
-
-
-
-
-
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
-
-
-
-
-
-
-
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
-
336,714 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


